X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs TORRENT PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD TORRENT PHARMA BIOCON LTD/
TORRENT PHARMA
 
P/E (TTM) x 36.6 26.6 137.8% View Chart
P/BV x 4.9 6.5 74.8% View Chart
Dividend Yield % 1.5 3.1 49.5%  

Financials

 BIOCON LTD   TORRENT PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-16
TORRENT PHARMA
Mar-16
BIOCON LTD/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs4961,720 28.8%   
Low Rs3971,134 35.0%   
Sales per share (Unadj.) Rs174.3394.5 44.2%  
Earnings per share (Unadj.) Rs44.8101.8 44.0%  
Cash flow per share (Unadj.) Rs56.9116.3 48.9%  
Dividends per share (Unadj.) Rs5.0040.00 12.5%  
Dividend yield (eoy) %1.12.8 40.0%  
Book value per share (Unadj.) Rs202.8200.3 101.3%  
Shares outstanding (eoy) m200.00169.22 118.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.63.6 70.8%   
Avg P/E ratio x10.014.0 71.0%  
P/CF ratio (eoy) x7.812.3 63.9%  
Price / Book Value ratio x2.27.1 30.9%  
Dividend payout %11.239.3 28.4%   
Avg Mkt Cap Rs m89,220241,435 37.0%   
No. of employees `0004.410.9 40.5%   
Total wages/salary Rs m6,3638,559 74.3%   
Avg. sales/employee Rs Th7,894.56,129.6 128.8%   
Avg. wages/employee Rs Th1,441.2785.8 183.4%   
Avg. net profit/employee Rs Th2,029.71,581.3 128.4%   
INCOME DATA
Net Sales Rs m34,85466,764 52.2%  
Other income Rs m8452,156 39.2%   
Total revenues Rs m35,69968,920 51.8%   
Gross profit Rs m8,20027,204 30.1%  
Depreciation Rs m2,4232,461 98.5%   
Interest Rs m1021,859 5.5%   
Profit before tax Rs m6,52025,041 26.0%   
Minority Interest Rs m-7440 248,000.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5,754-1,403 -410.2%   
Tax Rs m2,5696,414 40.1%   
Profit after tax Rs m8,96117,224 52.0%  
Gross profit margin %23.540.7 57.7%  
Effective tax rate %39.425.6 153.8%   
Net profit margin %25.725.8 99.7%  
BALANCE SHEET DATA
Current assets Rs m39,93246,622 85.7%   
Current liabilities Rs m16,27632,843 49.6%   
Net working cap to sales %67.920.6 328.9%  
Current ratio x2.51.4 172.8%  
Inventory Days Days5474 72.1%  
Debtors Days Days8679 109.1%  
Net fixed assets Rs m39,10139,029 100.2%   
Share capital Rs m1,000846 118.2%   
"Free" reserves Rs m38,59131,400 122.9%   
Net worth Rs m40,55633,890 119.7%   
Long term debt Rs m20,72418,637 111.2%   
Total assets Rs m84,81690,136 94.1%  
Interest coverage x64.914.5 448.6%   
Debt to equity ratio x0.50.5 92.9%  
Sales to assets ratio x0.40.7 55.5%   
Return on assets %10.721.2 50.5%  
Return on equity %22.150.8 43.5%  
Return on capital %19.048.5 39.1%  
Exports to sales %30.743.3 70.9%   
Imports to sales %20.46.9 296.9%   
Exports (fob) Rs m10,71728,934 37.0%   
Imports (cif) Rs m7,1054,584 155.0%   
Fx inflow Rs m11,78929,185 40.4%   
Fx outflow Rs m8,3936,021 139.4%   
Net fx Rs m3,39623,165 14.7%   
CASH FLOW
From Operations Rs m5,26427,132 19.4%  
From Investments Rs m-9,540-7,014 136.0%  
From Financial Activity Rs m10,867-14,352 -75.7%  
Net Cashflow Rs m6,5915,767 114.3%  

Share Holding

Indian Promoters % 40.4 71.5 56.5%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 7.0 119.7%  
FIIs % 10.7 12.6 84.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 8.8 226.1%  
Shareholders   109,995 26,511 414.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare BIOCON LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Amid Fed and ECB Minutes, L&T, Power Grid & IOC Among Other Top Stocks to Watch Out Today(Pre-Open)

On Thursday, Indian share markets oscillated between green and red in a broad range throughout the day and ended the session with marginal gains, with Nifty holding 9,900 mark.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Aug 17, 2017 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - TORRENT PHARMA COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS